±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 887  |  »Ø¸´: 5
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

mm1988

гæ (СÓÐÃûÆø)

[ÇóÖú] ÖÊÁ¿±ê×¼ÇóÖú ÒÑÓÐ2È˲ÎÓë

µâº£´¼×¢ÉäÒºµÄÖÊÁ¿±ê×¼   Iohexol Injection, BP ¡¢EP
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

mm1988

гæ (СÓÐÃûÆø)

ÒýÓûØÌû:
2Â¥: Originally posted by xdx1984 at 2015-05-18 13:54:22
²éÁËһϣ¬Ö»ÓÐÃÀ¹úÒ©µä±ê×¼£¬Ã²ËÆÃ»ÓÐBPEPµÄ¡£

Ô­À´ÊÇÕâÑù
6Â¥2015-05-19 09:40:08
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 6 ¸ö»Ø´ð

xdx1984

ľ³æ (ÕýʽдÊÖ)

²éÁËһϣ¬Ö»ÓÐÃÀ¹úÒ©µä±ê×¼£¬Ã²ËÆÃ»ÓÐBPEPµÄ¡£
2Â¥2015-05-18 13:54:22
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

534760595

½ð³æ (СÓÐÃûÆø)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
mm1988: ½ð±Ò+2, ¡ï¡ï¡ïºÜÓаïÖú, USP38ÕâÊÇÔÚÄÄÀïÕҵģ¬ÃÀ¹úÒ©µäÂÛ̳Âð£¿Èç¹ûÊÇÄܲ»Äܽ̽ÌÎÒÔõô²é£¬×¢²áÁËÕ˺Ų»»á²é£¬ºÃ²ÑÀ¢ 2015-05-19 09:41:22
USP38
Iohexol Injection
DEFINITION
Iohexol Injection is a sterile solution of Iohexol in Water for Injection. It contains NLT 95.0% and NMT 105.0% of the labeled amount of iohexol (C19H26I3N3O9) as organically bound iodine. It may contain small amounts of suitable buffers and Edetate Calcium Disodium as a stabilizer. Iohexol Injection intended for intravascular or intrathecal use contains no antimicrobial agents.
IDENTIFICATION
•  A. The retention times of the major peaks of the Sample solution correspond to those of the System suitability solution, as obtained in the test for Organic Impurities.
ASSAY
•  Procedure
Sample:  A volume of Injection equivalent to 300 mg of iodine
Analysis:  Transfer the Sample to a glass-stoppered, 250-mL conical flask. Add 25 mL of 1.25 N sodium hydroxide and 500 mg of powdered zinc, connect the flask to a reflux condenser, and reflux the solution for 1 h. Cool the flask to room temperature, rinse the condenser with 20 mL of water, disconnect the flask from the condenser, and filter the mixture. Rinse the flask and the filter thoroughly with small portions of water, adding the rinsings to the filtrate. Add 5 mL of glacial acetic acid, and titrate with 0.1 N silver nitrate VS. Each mL of 0.1 N silver nitrate is equivalent to 27.37 mg of C19H26I3N3O9.
Acceptance criteria:  95.0%¨C105.0%
IMPURITIES
•  Organic Impurities
Solution A:  Acetonitrile
Solution B:  Water
Mobile phase:  The percentage of Solution A increases from 1% to 13% at a rate of 0.2%/min.
System suitability solution:  1.5 mg/mL, 0.0075 mg/mL, and 0.0069 mg/mL each of USP Iohexol RS, USP Iohexol Related Compound A RS, and USP Iohexol Related Compound C RS in water
Sample solution:  1.5 mg/mL of Iohexol
Chromatographic system  
(See Chromatography 621, System Suitability.)
Mode:  LC
Detector:  UV 254 nm
Column:  4.6-mm ¡Á 25-cm stainless steel column; packing L1
Flow rate:  1.0 mL/min
Injection volume:  10 µL
System suitability  
Sample:  System suitability solution
[Note¡ªThe relative retention times for the exo-isomer of iohexol and the O-alkylated compounds are 1.0 and between 1.1 and 1.4, respectively. ]
[Note¡ªThe peak area of iohexol related compound C is 0.5% ¡À 0.1% compared to the total area of all the peaks in the chromatogram. ]
Suitability requirements  
Resolution:  NLT 20.0 between iohexol related compound A and iohexol related compound C
Analysis  
Sample:  Sample solution
Excluding peaks with retention times between 0.84 (relative to the endo-isomer of iohexol, which is the first main peak) and 1.0, calculate the percentage of O-alkylated compounds and any other individual impurity peak, in the portion of Iohexol taken:
Result = (rU/rT) ¡Á 100

rU = = peak response of each impurity
rT = = sum of all the peak responses

Acceptance criteria  
Individual impurity:  NMT 0.6% of O-alkylated compounds; NMT 0.1% of any other individual impurity
Total impurities:  NMT 0.3%, excluding O-alkylated compounds
SPECIFIC TESTS
•  Bacterial Endotoxins Test 85: NMT 0.2 USP Endotoxin Unit per 50 mg of iodine
•  pH 791: 6.8¨C7.7
•  Particulate Matter in Injections 788: The Injection labeled for intrathecal use meets the requirements for small-volume injections.
•  Free Iodide: Transfer 5.0 mL of Injection to a suitable container, add 20 mL of water, and titrate with 0.001 N silver nitrate VS using a silver electrode in combination with an appropriate reference electrode. Each mL of 0.001 N silver nitrate is equivalent to 0.1269 mg of iodine.
Acceptance criteria:  NMT 0.02%, based on the content of iohexol
•  Injections 1: Meets the requirements
ADDITIONAL REQUIREMENTS
•  Packaging and Storage: Preserve Injection intended for intravascular or intrathecal use in single-dose or multiple-dose plastic or Type I glass containers. Store at controlled room temperature, protected from light. Do not freeze.
•  Labeling: Label containers of Injection to direct the user to discard any unused portion. The labeling states also that it is not to be used if it is discolored or contains a precipitate. Label it also to state its routes of administration. When the specific dose strength is not intended for intrathecal use, label it to indicate ¡°serious injury can occur if given by intrathecal route¡±.
•  USP Reference Standards 11
USP Endotoxin RS
USP Iohexol RS  
USP Iohexol Related Compound A RS
5-(Acetylamino)-N,N¢-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide.
USP Iohexol Related Compound C RS
N,N¢-Bis(2,3-dihydroxypropyl)-5-nitro-1,3-benzenedicarboxamide.
3Â¥2015-05-18 16:43:55
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

mxx7456

гæ (СÓÐÃûÆø)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
USPµÄ×îаæÊDz»ÊÇÒª¹ºÂòµÄ£¬Ò»°ãºÃÏñ¶¼²é²»µ½
4Â¥2015-05-18 17:18:02
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ѹ¹ú¼ÒÒ»ÇøÏߣ¬Çóµ¼Ê¦ÊÕÁô£¬Óж÷±ØÐ»£¡ +7 ÃÔÈ˵Ĺþ¹þ 2026-03-28 7/350 2026-03-28 16:47 by ´ß»¯´ó°×
[¿¼ÑÐ] 394Çóµ÷¼Á +3 ºÃʶàÄ¥¾²ºò¼ÑÒ 2026-03-26 5/250 2026-03-28 14:24 by ÌÆãå¶ù
[¿¼ÑÐ] 311Çóµ÷¼Á +4 ¶¬Ê®Èý 2026-03-24 4/200 2026-03-28 13:17 by ÌÆãå¶ù
[¿¼ÑÐ] 085602 307·Ö Çóµ÷¼Á +7 ²»ÖªµÀ½Ðʲô£¡ 2026-03-26 7/350 2026-03-28 09:57 by ÉñÂí¶¼²»¶®
[¿¼ÑÐ] ²ÄÁÏÇóµ÷¼Á Ò»Ö¾Ô¸¹þ¹¤´ó×Ü·Ö298·Ö£¬Ç°Èý¿Æ223·Ö +5 dongfang59 2026-03-27 5/250 2026-03-28 04:53 by wxiongid
[¿¼ÑÐ] 352·Ö »¯¹¤Óë²ÄÁÏ +5 º£Äɰٴ¨Ly 2026-03-27 5/250 2026-03-28 03:39 by fmesaito
[¿¼ÑÐ] 279 ·Ö Çóµ÷¼Á +4 ˯¸öºÃ¾õ_16 2026-03-24 4/200 2026-03-27 15:05 by ×íÔÚ·çÀï
[¿¼ÑÐ] 316Çóµ÷¼Á +5 Pigcasso 2026-03-24 5/250 2026-03-27 12:10 by zhshch
[¿¼ÑÐ] ¿¼Ñе÷¼Á +10 ºôºô£¿~+123456 2026-03-24 10/500 2026-03-27 11:46 by wangjy2002
[¿¼ÑÐ] 333Çóµ÷¼Á +3 questionÍì·ç 2026-03-23 3/150 2026-03-27 11:29 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] 0703»¯Ñ§Ò»Ö¾Ô¸ÄϾ©Ê¦·¶´óѧ303Çóµ÷¼Á +3 zzffylgg 2026-03-24 3/150 2026-03-27 10:42 by shangxh
[¿¼ÑÐ] ²ÄÁÏѧ˶£¬Çóµ÷¼Á 6+5 ÌǺù«888ll 2026-03-22 10/500 2026-03-27 08:18 by hypershenger
[¿¼ÑÐ] ×Ü·Ö293Çóµ÷¼Á +6 ¼ÓÒ»Ò»¾Å 2026-03-25 8/400 2026-03-26 13:30 by yujianx
[Óлú½»Á÷] ÓлúºÏ³ÉÇóÖú 20+3 FENGSHUJEI 2026-03-23 5/250 2026-03-24 19:31 by 88817753
[¿¼ÑÐ] »¯¹¤×¨Ë¶Çóµ÷¼Á +3 questionÍì·ç 2026-03-24 3/150 2026-03-24 18:48 by jhhcooi
[¿¼ÑÐ] Ò»Ö¾Ô¸ºÓ±±¹¤Òµ´óѧ0817»¯¹¤278·ÖÇóµ÷¼Á +7 jhybd 2026-03-23 12/600 2026-03-24 09:03 by jhybd
[¿¼ÑÐ] 284Çóµ÷¼Á +3 yanzhixue111 2026-03-23 6/300 2026-03-23 22:58 by pswait
[¿¼ÑÐ] 384Çóµ÷¼Á +3 ×Óϵ²© 2026-03-22 6/300 2026-03-23 21:45 by ×Óϵ²©
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖØÇì´óѧ085700×ÊÔ´Óë»·¾³£¬×Ü·Ö308Çóµ÷¼Á +7 īīĮ 2026-03-23 8/400 2026-03-23 20:36 by Creta
[¿¼ÑÐ] Çóµ÷¼ÁÒ»Ö¾Ô¸º£´ó£¬0703»¯Ñ§Ñ§Ë¶304·Ö£¬Óдó´´ÏîÄ¿£¬Ëļ¶Òѹý +6 ÐÒÔËÁ¨Á¨ 2026-03-22 10/500 2026-03-22 20:10 by edmund7
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û